Literature DB >> 7565624

Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

C C Felder1, K E Joyce, E M Briley, J Mansouri, K Mackie, O Blond, Y Lai, A L Ma, R L Mitchell.   

Abstract

The recently cloned CB2 cannabinoid receptor subtype was stably transfected into AtT-20 and Chinese hamster ovary cells to compare the binding and signal transduction properties of this receptor with those of the CB1 receptor subtype. The binding of [3H]CP 55,940 to both CB1 and CB2 was of similar high affinity (2.6 and 3.7 nM, respectively) and saturable. In competitive binding experiments, (-)-delta 9-tetrahydrocannabinol and CP 55,940 were equipotent at the CB1 and CB2 receptors, but WIN 55212-2 and cannabinol bound with higher affinity to the CB2 than the CB1 receptor. HU 210 had a higher affinity for the CB1 receptor. Anandamide, a recently identified endogenous cannabinoid agonist, was essentially equipotent at both receptor subtypes. The structurally related fatty acid ethanolamides dihomo-gamma-linolenylethanolamide and mead ethanolamide also bound with relatively equal affinity to both receptors, but adrenylethanolamide had a higher affinity for the CB1 receptor. The rank order of potency and efficacy for binding of the selected agonists to the CB1 and CB2 receptors was mimicked in functional inhibition of cAMP accumulation experiments for all compounds tested. Both CB1 and CB2 receptors couple to the inhibition of cAMP accumulation that was pertussis toxin sensitive. SR141716A, a CB1 receptor antagonist, was a poor antagonist at the CB2 receptor in both binding and functional inhibition of cAMP accumulation experiments. When expressed in AtT-20 cells, the CB1 receptor mediated an inhibition of Q-type calcium channels and an activation of inward rectifying potassium channels. In contrast, the CB2 receptor did not modulate the activity of either channel under identical assay conditions. Similar to results obtained for CB1 receptor, the CB2 receptor did not couple to the activation of phospholipases A2, C, or D or to the mobilization of intracellular Ca2+. Except for its inability to couple to the modulation of Q-type calcium channels or inwardly rectifying potassium channels, the CB1 and CB2 receptors display similar pharmacological and biochemical properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7565624

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  218 in total

1.  Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

Authors:  R A Ross; H C Brockie; L A Stevenson; V L Murphy; F Templeton; A Makriyannis; R G Pertwee
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Cannabinoids throw up a conundrum.

Authors:  DeWayne Townsend; Stanley A Thayer; David R Brown
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

3.  Cannabinoid receptor-G protein interactions: G(alphai1)-bound structures of IC3 and a mutant with altered G protein specificity.

Authors:  Amy L Ulfers; Jonathan L McMurry; Alexander Miller; Ligong Wang; Debra A Kendall; Dale F Mierke
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

Review 4.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

5.  Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Authors:  Jijun J Xu; Philippe Diaz; Fanny Astruc-Diaz; Suzanne Craig; Elizandro Munoz; Mohamed Naguib
Journal:  Anesth Analg       Date:  2010-06-03       Impact factor: 5.108

Review 6.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 7.  Lipidomic analysis of endocannabinoid metabolism in biological samples.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

Review 8.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 9.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

10.  Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.

Authors:  R White; W S Ho; F E Bottrill; W R Ford; C R Hiley
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.